INTRODUCTION
Identifying multiple proteins in a single sample has advantages. In cancer diagnostics, specificity can be improved with more than one marker (1, 2) . For example, cancer antigen 125 (CA 125) is elevated in different types of cancer such as endometrial cancer (3), renal cell carcinoma (4) , and ovarian cancer (5) . In addition, if different diseases have overlapping clinical symptoms, the qualitative and quantitative assessment of multiple antigens may provide diagnosis. So, it has been reported that the same CA 125 antigen is also elevated in noncancerous conditions, such as endometriosis (6) , mitral valve stenosis (7) , and hypothyroidism (8, 9) . Therefore, if other markers can be identified to categorize the diseases, the potential benefits of measuring multiple antigens simultaneously from the same sample are obvious. Currently, technology is available for measuring multiple antigens, but the clinical interpretation is not available.
There are a variety of different methods available for identifying multiple antigens in the same sample simultaneously. The most common method for measuring multiple antigens from a complex mixture of proteins has been by two-dimensional gel electrophoresis (2-DE) (10, 11) , sometimes followed by identification by tandem mass spectrometry. Also available are protein arrays that require antibodies of known specificity and affinity (10, 12) that are immobilized on a surface. Time-of-flight mass spectrometer techniques like matrix-assisted laser desorption/ionization (MALDI) and surface-enhanced laser desorption/ ionization (SELDI) have also been used for identifying multiple antigens in complex mixtures (13, 14) .
Many methods allow parallel protein identification, but measurement of their concentrations is an important indicator used in both life science research and clinical practice (15) . Arrays of antibodies for simultaneous antigen quantification are considered the most accurate (10, 12) . Enzyme-linked immunosorbent assay (ELISA) microarrays were first reported as printed arrays on glass (16) . These arrays had 144 spots each that corresponded to the location of a well in a microtiter plate. A 16-spot array printed onto nitrocellulose attached to a microscope slide has also been reported (17) . Microarrays can now be printed directly onto the bottom of a 96-well plate and have been used by different investigators and companies (15, 18 
microELISA Analysis
Following testing at ARUP, the samples were shipped overnight in dry ice, stored at -20°C, and used within 1 year. Samples were never subjected to more than three freeze-thaw cycles. The nine microELISA assays were developed using commercially available antibodies that were diluted in phosphate-buffered saline (PBS), pH 7.4, and used at the concentrations given in Table 1 . Antibodies and standardized antigens used in the microELISA were different than those used in the commercially available assays. Nine 50-nL spots of capture antibody were arranged in a 3 × 3 grid in each well of a 96-well plate (Greiner Bio-One, Monroe, NC, USA) ( Figure 1 ) at 80% relative humidity using a PixSys™ Cartesian Dispensing system (Cartesian Technologies, Irvine, CA, USA). The plates were incubated for 4 h at 37°C (80% relative humidity) and then blocked in 100 μL/well Super AAA buffer (ScyTek, Logan, UT, USA) for 10 min at 20°C with shaking on an orbital shaker. All incubations to follow were performed similarly with shaking. After removal of the blocking solution, 30 μL sample or a 6-point standard curve (Lyphochek ® Tumor Marker Control; 
Conventional ELISAs
The same antibodies used in the microELISA format were also tested in a conventional ELISA format. This was to determine if there was any difference in results between the microELISA format and ELISAs that had been set up under conventional conditions. Eight different conventional ELISAs were performed. Each conventional ELISA had a separate random sample set ranging from 50 to 96 samples. The microELISA assays were performed at the same time as the conventional ELISAs on the same sample set to ensure similar reaction conditions. The conventional ELISA was performed identically to the microELISA except that antibodies were coated at a concentration of 2 μg/mL in PBS, pH 7.4, and the substrate incubation times ranged from 1 min to 1 h.
Precision Studies and Statistical Analysis
The array was tested for reproducibility over the course of 30 days by the same technician using different lots of reagents and plates. Twentyfour different 96-well plates were run with serum samples in triplicate, and the calibration curve in duplicate. Interassay precision was determined as the coefficient of variation (cv) of test samples at different dilutions over a period of 30 days (n = 24). Intra-assay precision was calculated by determining the cv over 96 different wells on the same plate. The test samples were diluted to be within the dynamic range of the assay calibration curve. Testing ranges were determined by regression statistics obtained from a comparison of methods study used to calculate the reference limits of a new method (21) . The lower limits of detection (LLD) for each assay were calculated by adding the mean of the blank to two times the standard deviation of the blank. 
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microELISA array results were correlated to the reference methods and conventional ELISAs using Deming regression, which takes into account the uncertainty of both the reference and experimental assays. Statistical significance was determined by the 95% confidence intervals for the slope and intercept. In addition, assignment of "high quality" to an assay required that the intervals included a slope of 1 and an intercept of 0. Deming regressions were determined by EP Evaluator online at www.dgrhoads2.com.
RESULTS AND DISCUSSION
Nine different ELISAs were developed and multiplexed in array format in each well of a 96-well plate. The antigens AFP, PSA, CEA, CA 125, CA 15-3, CA 19-9, β-hCG, LH, and FSH were analyzed simultaneously. Cross-reactivity tests of nearly 14,000 points were performed by using each capture antibody with all potential combinations of antigen and detection antibodies to ensure minimal crossreactivity with nonspecific factors (data not shown). The only cross-reactivity detected was using the antibody for CA 19-9, which detects Sial Lewis A carbohydrate moieties. However, assaying these samples with and without the CA 19-9 antibody did not affect the values for the microELISA.
The overall cv over 30 days was 12.63% with intra-assay variation contributing 7.26%. R 2 values were calculated for the standard curves of each antigen. Six-point standard curves, five serial dilutions of one to two, and a negative control were used, with the exception of PSA, where only three points were within the analytical measurement range (Figure 2 ). The R 2 values for the standard curves were 0.99 for FSH, CA 125, CA 19-9, β-hCG, CEA, and PSA; 0.98 for LH; 0.92 for AFP; and 0.88 for CA 15-3. The sensitivity and useful ranges of the microELISA were compared with conventional clinical assays ( Table 2 ). The CA 15-3, CEA, β-hCG, and CA 19-9 assays were more sensitive by microELISA, while total PSA, CA 125, and LH assays were more sensitive by clinical laboratory testing. The β-hCG assay had a broader analytical measurement range by microELISA, while total PSA, CA 19-9, LH, and FSH had a broader analytical measurement range by clinical laboratory testing.
Deming regression analysis indicated that four of the nine micro-ELISA assays (AFP, CA 125, CA 15-3, and CA 19-9) were not statistically different from the clinical assays (Table 3 and Figure 3 ). For the remaining antigens, either the slopes were different with a proportional difference between the methods, and/ or the intercepts were different with a 
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constant offset between assays (22, 23) . The PSA, CEA, β-hCG, and FSH had both a proportional and constant difference between assays. For LH there was a constant offset between the clinical assay and the microELISA. One of the challenges in antibody microarray development is to match the specificity of antibodies used in conventional assays. For example, posttranslational modifications of FSH may differ between patients, and the antibodies recognizing FSH in the microELISA and the conventional assay may recognize different epitopes (24, 25) . To test this hypothesis, conventional ELISAs were performed using identical antibodies as those in the microELISA to confirm that the differences seen compared with the commercial assays were due to different antibodies. Five out of the eight assays were statistically identical according to the Deming regressions ( Figure 4 and Table 4 ). This suggests that different antibodies are at least partly responsible for differences between the microELISA and the clinical platforms. Antibody variation is a general problem for all arrays using an immunoassay approach, and the development of databases of antibody reactivity will improve comparisons (26) .
High-quality microELISA assays can be developed with characteristics similar to macroassays run on clinical platforms. Further improvements in antibody selection are expected to improve correlations with existing assays. microELISA arrays have promise for clinical diagnostics, especially when the available sample is limited. With specific antigen or biochemical panels, diagnosis and prognosis may increase in accuracy, leading to lower patient morbidity and mortality. 
